Fintel reports that on November 4, 2024, Leerink Partners initiated coverage of Zura Bio (NasdaqCM:ZURA) with a Outperform ...

In a report released on November 1, Jonathan Chang from Leerink Partners reiterated a Buy rating on Molecular Partners (MOLN – Research ...

Leerink Partners CIO Jeff Gerson on how the firm realigned its technology strategies and services after it demerged from SVB ...

Leerink Partners CIO Jeff Gerson on how the firm realigned its technology strategies and services after it demerged from SVB ...

On Monday, Envista Holdings Corp (NVST) stock saw a modest uptick, ending the day at $21.28 which represents a slight increase of $0.34 or 1.62% from the prior close of $20.94. The stock opened at $21 ...

BOSTON, Nov. 1, 2024 /PRNewswire/ -- Leerink Partners, a leading investment bank specializing in healthcare, is pleased to announce that Tom Davidson has joined as Co-President of the firm and Co ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.21% of ...

Andrew Berens, an analyst from Leerink Partners, maintained the Buy rating on Merus (MRUS – Research Report). The associated price target ...

On Friday, Leerink Partners maintained an Outperform rating on shares of Merck & Co., Inc. (NYSE:MRK), citing ongoing concerns about the pharmaceutical giant's Gardasil vaccine as a key factor ...

On Friday, Leerink Partners maintained an Outperform rating on shares of Merck & Co., Inc. (NYSE:MRK), citing ongoing concerns about the pharmaceutical giant's Gardasil vaccine as a key factor ...

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...